Fludarabine
Lymphoma
National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 71/ 100
- Competitive Position
- 65/ 100
Competitive context
288 Active assets in the Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation | Phase 4 | BBB |
VINBLASTINE Intensity Therapeutics, Inc. | Phase 4 | BBB |
BLEOMYCIN Shandong Provincial Hospital | Phase 4 | BB |
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
Ifosfamide Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →